Wendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics (NASDAQ:RAPPGet Free Report) Director Wendy B. Young purchased 6,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $61,260. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Rapport Therapeutics Price Performance

Shares of NASDAQ:RAPP opened at $10.51 on Friday. The business’s 50 day simple moving average is $13.54 and its 200-day simple moving average is $18.74. Rapport Therapeutics has a 12 month low of $6.43 and a 12 month high of $29.74.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors have recently modified their holdings of RAPP. Wells Fargo & Company MN lifted its stake in Rapport Therapeutics by 38.9% in the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company’s stock valued at $86,000 after buying an additional 1,352 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics in the 3rd quarter valued at approximately $34,000. The Manufacturers Life Insurance Company lifted its stake in Rapport Therapeutics by 2.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company’s stock valued at $1,584,000 after buying an additional 1,828 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Rapport Therapeutics in the 4th quarter valued at approximately $34,000. Finally, Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the 4th quarter valued at approximately $41,000.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.

Featured Articles

Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.